Amicus Therapeutics Inc. (NASDAQ:FOLD) dropped 3.3% on Wednesday . The company traded as low as $6.66 and last traded at $6.74, with a volume of 864,544 shares trading hands. The stock had previously closed at $6.97.

FOLD has been the topic of a number of recent analyst reports. Bank of America Corp. initiated coverage on shares of Amicus Therapeutics in a research note on Wednesday, May 18th. They issued a “buy” rating and a $10.00 target price on the stock. Leerink Swann reiterated an “outperform” rating and set a $17.00 price target on shares of Amicus Therapeutics in a research report on Wednesday, June 1st. Zacks Investment Research upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $6.75 price target on the stock in a research report on Monday, July 25th. Finally, Chardan Capital set a $15.00 price target on shares of Amicus Therapeutics and gave the company a “buy” rating in a research report on Thursday, August 11th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $12.19.

The stock has a 50-day moving average of $6.61 and a 200 day moving average of $6.93. The stock’s market cap is $950.91 million.

Amicus Therapeutics (NASDAQ:FOLD) last posted its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.33) by $0.07. On average, equities analysts forecast that Amicus Therapeutics Inc. will post ($1.35) EPS for the current fiscal year.

In related news, insider Perceptive Advisors Llc sold 1,100,000 shares of the firm’s stock in a transaction dated Thursday, August 25th. The stock was sold at an average price of $6.81, for a total transaction of $7,491,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Jay Barth sold 20,916 shares of the firm’s stock in a transaction that occurred on Wednesday, July 27th. The shares were sold at an average price of $7.00, for a total value of $146,412.00. Following the completion of the sale, the insider now directly owns 25,458 shares in the company, valued at $178,206. The disclosure for this sale can be found here.

Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.